{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:13Z","timestamp":1790456293075,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited longitudinal data are available on immune response to mRNA SARS-CoV-2 vaccination in people living with HIV (PLWHIV); therefore, new evidence on induction and persistence of spike-specific antibodies and B cells is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this pilot study we investigated the spike-specific humoral and B cell responses up to six months after vaccination with two doses of mRNA vaccines in 84 PLWHIV under antiretroviral therapy compared to 79 healthy controls (HCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Spike-specific IgG persisted six months in PLWHIV with no significant differences compared to HCs, even though a significantly lower IgG response was observed in patients with CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells &lt;\u00a0350\/mmc. The frequency of subjects with antibodies capable of inhibiting ACE2\/RBD binding was comparable between PLWHIV and HCs a month after the second vaccine dose, then a higher drop was observed in PLWHIV. A comparable percentage of spike-specific memory B cells was observed at month six in PLWHIV and HCs. However, PLWHIV showed a higher frequency of spike-specific IgD\n                      <jats:sup>-<\/jats:sup>\n                      CD27\n                      <jats:sup>-<\/jats:sup>\n                      double-negative memory B cells and a significantly lower rate of IgD\n                      <jats:sup>-<\/jats:sup>\n                      CD27\n                      <jats:sup>+<\/jats:sup>\n                      Ig-switched memory B cells compared to HCs, suggesting a reduced functionality of the antigen-specific memory B population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The mRNA vaccination against SARS-CoV-2 elicits humoral and B cell responses quantitatively similar between PLWHIV and HCs, but there are important differences in terms of antibody functionality and phenotypes of memory B cells, reinforcing the notion that tailored vaccination policies should be considered for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-023-00245-5","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T13:05:28Z","timestamp":1675083928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-0546","authenticated-orcid":false,"given":"Jacopo","family":"Polvere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabiria","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Rancan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zirpoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-7433","authenticated-orcid":false,"given":"Simone","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-8061","authenticated-orcid":false,"given":"Fabio","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tumbarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ciabattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1337","authenticated-orcid":false,"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-7325","authenticated-orcid":false,"given":"Donata","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"245_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/cid\/ciaa863","volume":"72","author":"M Fung","year":"2021","unstructured":"Fung, M. & Babik, J. M. COVID-19 in immunocompromised hosts: what we know so far. Clin. Infect. Dis. 72, 340\u2013350 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"245_CR2","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/S2352-3018(21)00240-X","volume":"8","author":"DK Nomah","year":"2021","unstructured":"Nomah, D. K. et al. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV 8, e701\u2013e710 (2021).","journal-title":"Lancet HIV"},{"key":"245_CR3","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV 8, e690\u2013e700 (2021).","journal-title":"Lancet HIV"},{"key":"245_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/QAD.0000000000003132","volume":"36","author":"J del Amo","year":"2022","unstructured":"del Amo, J., Polo, R., Moreno, S., Jarr\u00edn, I. & Hern\u00e1n, M. A. SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment. AIDS 36, 161\u2013168 (2022).","journal-title":"AIDS"},{"key":"245_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26137-7","volume":"12","author":"A Alrubayyi","year":"2021","unstructured":"Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat. Commun. 12, 5839 (2021).","journal-title":"Nat. Commun"},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.vaccine.2013.04.033","volume":"31","author":"M Fabbiani","year":"2013","unstructured":"Fabbiani, M. et al. HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. Vaccine 31, 2914\u20132918 (2013).","journal-title":"Vaccine"},{"key":"245_CR7","doi-asserted-by":"publisher","first-page":"e0156523","DOI":"10.1371\/journal.pone.0156523","volume":"11","author":"F Lombardi","year":"2016","unstructured":"Lombardi, F. et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study. PLoS ONE 11, e0156523 (2016).","journal-title":"PLoS ONE"},{"key":"245_CR8","doi-asserted-by":"publisher","unstructured":"Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab. Sci. 1\u201318 https:\/\/doi.org\/10.1080\/10408363.2022.2038539 (2022).","DOI":"10.1080\/10408363.2022.2038539"},{"key":"245_CR9","doi-asserted-by":"publisher","unstructured":"Pettini, E. et al. A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2021006599 (2022).","DOI":"10.1182\/bloodadvances.2021006599"},{"key":"245_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/biomedicines9101480","volume":"9","author":"F Fiorino","year":"2021","unstructured":"Fiorino, F. et al. The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose. Biomedicines 9, 1480 (2021).","journal-title":"Biomedicines"},{"key":"245_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00281-020-00821-0","volume":"42","author":"A Ciabattini","year":"2020","unstructured":"Ciabattini, A. et al. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. Semin. Immunopathol. 42, 619\u2013634 (2020).","journal-title":"Semin. Immunopathol."},{"key":"245_CR12","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","volume":"35","author":"JA Ruddy","year":"2021","unstructured":"Ruddy, J. A. et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS 35, 2399\u20132401 (2021).","journal-title":"AIDS"},{"key":"245_CR13","doi-asserted-by":"publisher","unstructured":"Antinori, A. et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte Count. Clin. Infect. Dis. ciac238 https:\/\/doi.org\/10.1093\/cid\/ciac238 (2022).","DOI":"10.1093\/cid\/ciac238"},{"key":"245_CR14","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000003166","volume":"36","author":"N Hassold","year":"2022","unstructured":"Hassold, N. et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS 36, F1\u2013F5 (2022).","journal-title":"AIDS"},{"key":"245_CR15","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals. (US Food and Drug Administration, 2022)."},{"key":"245_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41565-022-01129-w","volume":"17","author":"G Guerrini","year":"2022","unstructured":"Guerrini, G., Magr\u00ec, D., Gioria, S., Medaglini, D. & Calzolai, L. Characterization of nanoparticles-based vaccines for COVID-19. Nat. Nanotechnol. 17, 570\u2013576 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"245_CR17","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3389\/fimmu.2021.740708","volume":"12","author":"A Ciabattini","year":"2021","unstructured":"Ciabattini, A. et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front. Immunol. 12, 3751 (2021).","journal-title":"Front. Immunol."},{"key":"245_CR18","doi-asserted-by":"publisher","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science https:\/\/doi.org\/10.1126\/science.abm0829 (2021).","DOI":"10.1126\/science.abm0829"},{"key":"245_CR19","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/jmv.27688","volume":"94","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Characterization of the significant decline in humoral immune response six months post\u2010SARS\u2010CoV\u20102 mRNA vaccination: a systematic review. J. Med. Virol. 94, 2939\u20132961 (2022).","journal-title":"J. Med. Virol."},{"key":"245_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00452-6","volume":"7","author":"ZL Brumme","year":"2022","unstructured":"Brumme, Z. L. et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines 7, 1\u201312 (2022).","journal-title":"NPJ Vaccines"},{"key":"245_CR21","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/jmv.27629","volume":"94","author":"E Milano","year":"2022","unstructured":"Milano, E. et al. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: a monocentric study in Bari, Italy. J. Med. Virol. 94, 2230\u20132236 (2022).","journal-title":"J. Med. Virol."},{"key":"245_CR22","doi-asserted-by":"crossref","unstructured":"Portillo, V. et al. Impact on HIV-1 RNA levels and antibody responses following SARS-CoV-2 vaccination in HIV-infected individuals. Front. Immunol. 12, 820126 (2022).","DOI":"10.3389\/fimmu.2021.820126"},{"key":"245_CR23","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.vaccine.2015.04.008","volume":"33","author":"Z Hu","year":"2015","unstructured":"Hu, Z. et al. HIV-associated memory B cell perturbations. Vaccine 33, 2524\u20132529 (2015).","journal-title":"Vaccine"},{"key":"245_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.18632\/aging.101229","volume":"9","author":"S Rinaldi","year":"2017","unstructured":"Rinaldi, S. et al. Paradoxical aging in HIV: immune senescence of B cells is most prominent in young age. Aging (Albany NY) 9, 1307\u20131322 (2017).","journal-title":"Aging (Albany NY)"},{"key":"245_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12502","volume":"275","author":"S Moir","year":"2017","unstructured":"Moir, S. & Fauci, A. S. B cell responses to HIV infection. Immunol. Rev. 275, 33\u201348 (2017).","journal-title":"Immunol. Rev."},{"key":"245_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Informat. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Informat."},{"key":"245_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cyto.a.20258","volume":"69A","author":"DR Parks","year":"2006","unstructured":"Parks, D. R., Roederer, M. & Moore, W. A. A new \u201cLogicle\u201d display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytom. Part A 69A, 541\u2013551 (2006).","journal-title":"Cytom. Part A"},{"key":"245_CR28","first-page":"2579","volume":"9","author":"Lvander Maaten","year":"2008","unstructured":"Maaten, Lvander & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579\u20132605 (2008).","journal-title":"J. Mach. Learn. Res."},{"key":"245_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.20411\/pai.v5i1.341","volume":"5","author":"A Muscatello","year":"2020","unstructured":"Muscatello, A. et al. Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection-results of italian network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathog. Immun. 5, 8\u201333 (2020).","journal-title":"Pathog. Immun."},{"key":"245_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/QAI.0000000000002525","volume":"86","author":"M Fabbiani","year":"2021","unstructured":"Fabbiani, M. et al. Integrase inhibitors use and cytomegalovirus infection predict immune recovery in people living with HIV starting first-line therapy. JAIDS J. Acquir. Immune Defic. Syndr. 86, 119\u2013127 (2021).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"245_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.mad.2009.08.003","volume":"130","author":"G Colonna-Romano","year":"2009","unstructured":"Colonna-Romano, G. et al. A double-negative (IgD\u2212CD27\u2212) B cell population is increased in the peripheral blood of elderly people. Mech. Ageing Dev. 130, 681\u2013690 (2009).","journal-title":"Mech. Ageing Dev."},{"key":"245_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/QAD.0000000000003135","volume":"36","author":"X Xu","year":"2022","unstructured":"Xu, X., Vesterbacka, J., Aleman, S. & Nowak, P. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV \u2013 but HIV viremia matters? AIDS 36, 479\u2013481 (2022).","journal-title":"AIDS"},{"key":"245_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/hiv.13202","volume":"23","author":"N Jedicke","year":"2022","unstructured":"Jedicke, N. et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med. 23, 558\u2013563 (2022).","journal-title":"HIV Med."},{"key":"245_CR34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 326, 1533\u20131535 (2021).","journal-title":"JAMA"},{"key":"245_CR35","doi-asserted-by":"crossref","unstructured":"Lombardi, A. et al. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study. Lancet Reg. Health Europe 13, 100287(2021).","DOI":"10.1016\/j.lanepe.2021.100287"},{"key":"245_CR36","doi-asserted-by":"publisher","first-page":"ofac089","DOI":"10.1093\/ofid\/ofac089","volume":"9","author":"L Tau","year":"2022","unstructured":"Tau, L. et al. SARS-CoV-2 humoral and cellular immune responses of patients with HIV after vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv Medical Center. Open Forum Infect. Dis. 9, ofac089 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"245_CR37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/hiv.13037","volume":"22","author":"C Hoffmann","year":"2021","unstructured":"Hoffmann, C. et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 22, 372\u2013378 (2021).","journal-title":"HIV Med."},{"key":"245_CR38","doi-asserted-by":"publisher","unstructured":"Woldemeskel, B. A. et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin. Infect. Dis. ciab648 https:\/\/doi.org\/10.1093\/cid\/ciab648 (2021).","DOI":"10.1093\/cid\/ciab648"},{"key":"245_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"245_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.13089","volume":"310","author":"A Sette","year":"2022","unstructured":"Sette, A. & Crotty, S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol. Rev. 310, 27\u201346 (2022).","journal-title":"Immunol. Rev."},{"key":"245_CR41","doi-asserted-by":"crossref","unstructured":"Pettini, E., Medaglini, D. & Ciabattini, A. Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2. Front. Immunol. 13, 1058748 (2022).","DOI":"10.3389\/fimmu.2022.1058748"},{"key":"245_CR42","doi-asserted-by":"crossref","unstructured":"Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front. Immunol. 10, 2458 (2019).","DOI":"10.3389\/fimmu.2019.02458"},{"key":"245_CR43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","volume":"188","author":"U Klein","year":"1998","unstructured":"Klein, U., Rajewsky, K. & K\u00fcppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (Memory) B cells. J. Exp. Med. 188, 1679\u20131689 (1998).","journal-title":"J. Exp. Med."},{"key":"245_CR44","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.4049\/jimmunol.178.10.6624","volume":"178","author":"C Wei","year":"2007","unstructured":"Wei, C. et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178, 6624\u20136633 (2007).","journal-title":"J. Immunol."},{"key":"245_CR45","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1084\/jem.20050879","volume":"202","author":"GRA Ehrhardt","year":"2005","unstructured":"Ehrhardt, G. R. A. et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J. Exp. Med. 202, 783\u2013791 (2005).","journal-title":"J. Exp. Med."},{"key":"245_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e6 (2018).","journal-title":"Immunity"},{"key":"245_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cei.13615","volume":"205","author":"Y Li","year":"2021","unstructured":"Li, Y., Li, Z. & Hu, F. Double\u2010negative (DN) B cells: an under\u2010recognized effector memory B cell subset in autoimmunity. Clin. Exp. Immunol. 205, 119\u2013127 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"245_CR48","doi-asserted-by":"crossref","unstructured":"Courey-Ghaouzi, A.-D., Kleberg, L. & Sundling, C. Alternative B cell differentiation during infection and inflammation. Front. Immunol. 13, 908034 (2022).","DOI":"10.3389\/fimmu.2022.908034"},{"key":"245_CR49","doi-asserted-by":"crossref","unstructured":"Azzolini, E. et al. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci. Alliance 5, 202201381 (2022).","DOI":"10.26508\/lsa.202201381"},{"key":"245_CR50","doi-asserted-by":"crossref","unstructured":"Fiorino, F. et al. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Front. Immunol. 13, 1017863 (2022).","DOI":"10.3389\/fimmu.2022.1017863"},{"key":"245_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32263-7","volume":"13","author":"A Vergori","year":"2022","unstructured":"Vergori, A. et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat. Commun. 13, 4922 (2022).","journal-title":"Nat. Commun"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00245-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T13:09:17Z","timestamp":1675084157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00245-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1038\/s43856-023-00245-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.01.22277132","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. M.F. received speakers\u2019 honoraria, support for travel to meetings, and\/or fees for attending advisory boards from Bristol Myers Squibb (BMS), Gilead, Janssen-Cilag, Merck Sharp and Dohme (MSD), and ViiV Healthcare. F.M. received support for travel to meetings from Angelini, she is principal investigator in sponsor study by TLS (Toscana Life Science) and by GSK Vaccine SRL and she is the contact person for a service contract between GSK Vaccine SRL and Department of Medical Biotechnologies, University of Siena, without receiving any personal remuneration. The other authors declare no conflict of interest regarding this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}